Nanobiotix has presented new data, translational during the workshop immunotherapy gold…

Data translationelles showing an activation of the immune system against tumors and cell invasive tumors (TILs) in Humans and in mice

Download the free guide
Boost your gains

Confirmation of the ability to transform tumors “cold” tumors “hot”, and potential treatment on the micro environment of the tumor
Opening potential in the treatment of metastases
Paris, France and Cambridge, Massachusetts, June 15, 2017 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a French company pioneer in nanomedicine in developing new therapeutic approaches for the treatment of cancer, has presented new data, translational during the workshop : “Immunotherapy workshop – Incorporating Radiation Oncology into Immunotherapy organized by the American Society of Radiation Oncology (ASTRO), the National Cancer Institute (NCI) and the Society for Immunotherapy of Cancer (SITC) in Bethesda, Maryland (USA), from 15 to 16 June 2017.

The mode of action of NBTXR3 provides a physical destruction local the cancer cells. In parallel, recently published data suggest that the product could generate a cell-death immunogenicity (Immunogenic cell death – ICD) which triggers a specific immune response against the tumor.

Most tumors respond little or not to therapies aimed to generate an antitumor immune response and are thus considered to be ” cold “. This lack of response is mainly due to the low immunogenicity of these tumors. The ability of NBTXR3 to induce cell death to be immunogenic (DCI) to the level of intratumoral could be key to increase the number of patients that can be helped by their immune system to fight their cancer.

Nanobiotix has presented new data, translational outcomes of its programme of Immuno-oncology :

“Hafnium oxide nanoparticle, a potent radiation enhancer for in-situ cancer vaccine” (June 15, 2017)

J. Galon1, Mr. Laé2, Z. Papai3, P. Rochaix4, L. C. Mangel5, F. Hermitte6, Z. Sapi7, Mr. Delannes4, T. Tornoczky5 , A. Vincent-Salomon2, V. Servois2, H. Brisse2, S. Paris8, A. Pottier8, and S. Bonvalot2 1INSERM, Paris, France, 2Institut Curie, Paris, France, 3Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary, 4Institut Universitaire du Cancer, Toulouse, France, 5Pecs University, Pecs, Hungary, 6HalioDx, Marseille, France, 7Semmelweis University, Budapest, Hungary, 8Nanobiotix, Paris, France.

Download the free guide
Boost your gains

Like this post? Please share to your friends:
Leave a Reply